CAR-T cell therapy: a potential new strategy against prostate cancer

Bibliographic Details
Title: CAR-T cell therapy: a potential new strategy against prostate cancer
Authors: Giuseppe Schepisi, Maria Concetta Cursano, Chiara Casadei, Cecilia Menna, Amelia Altavilla, Cristian Lolli, Claudio Cerchione, Giovanni Paganelli, Daniele Santini, Giuseppe Tonini, Giovanni Martinelli, Ugo De Giorgi
Source: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Publisher Information: BMJ Publishing Group, 2019.
Publication Year: 2019
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: T cells, Prostate cancer, CAR-T, Immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract Prostate cancer (PCa) is one of the main causes of cancer-related death in men. In the present immunotherapy era, several immunotherapeutic agents have been evaluated in PCa with poor results, possibly due to its low mutational burden. The recent development of chimeric antigen receptor (CAR)-T cell therapy redirected against cancer-specific antigens would seem to provide the means for bypassing immune tolerance mechanisms. CAR-T cell therapy has proven effective in eradicating hematologic malignancies and the challenge now is to obtain the same degree of in solid tumors, including PCa. In this study we review the principles that have guided the engineering of CAR-T cells and the specific prostatic antigens identified as possible targets for immunological and non-immunological therapies. We also provide a state-of-the-art overview of CAR-T cell therapy in PCa, defining the key obstacles to its development and underlining the mechanisms used to overcome these barriers. At present, although there are still many unanswered questions regarding CAR-T cell therapy, there is no doubt that it has the potential to become an important treatment option for urological malignancies.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2051-1426
Relation: http://link.springer.com/article/10.1186/s40425-019-0741-7; https://doaj.org/toc/2051-1426
DOI: 10.1186/s40425-019-0741-7
Access URL: https://doaj.org/article/382e39b0c7b64284b9a272daa75e320e
Accession Number: edsdoj.382e39b0c7b64284b9a272daa75e320e
Database: Directory of Open Access Journals
More Details
ISSN:20511426
DOI:10.1186/s40425-019-0741-7
Published in:Journal for ImmunoTherapy of Cancer
Language:English